Trending Alert: These 6 Companies Are Trending Now

Tickers Inside Powered by [FinancialMarketMovers.com]( Good Morning! Below is a list of 6 stocks that are trending with positive investor sentiment, news headlines, and buy ratings from top Wall Street analysts. Our editors are keeping an eye on these stocks and adding them to our watchlist to see if the momentum continues. --------------------------------------------------------------- Sponsor [Tiny Lithium Stock Surge!]( t miss out on this tiny stock poised to surge in a massive $183B market opportunity! [Get the Free Report]( --------------------------------------------------------------- [Boeing, BA]( Summary: The Boeing Co. is one of the largest defense contractors in the U.S. for its premier jet aircraft along with varied defense products. Its customers include domestic & foreign airlines, the U.S. DoD, the Department of Homeland Security, the NASA, other aerospace prime contractors, and certain U.S. government and commercial communications customers. It has 4 segments. Boeing Commercial Airplanes Segment develops, produces & markets commercial jets, and support services. The 3 units that comprise the Boeing Defense, Space & Security (BDS) segment are as follows: Boeing Military Aircraft, Network and Space Systems and Global Services and Support. Boeing Global Services Segment brings together certain Commercial Aviation Services businesses and BDS businesses. It provides parts, maintenance, modifications, logistics support, training, data analytics and information-based services. Boeing Capital Corp. Segment provides selective financing solutions for BDS segment government customers. Kenneth Herbert analyst at RBC Capital reiterated coverage on [Boeing (BA)](in the Industrials sector with a Buy rating and has set a price target of $275. Our data shows [Boeing]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $270.00. In addition, TradingView issued a Buy rating for [BA]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the complete breakdown on BA, please click here >>]( [Keros Therapeutics, KROS]( Summary: Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. Andrew Fein analyst at H.C. Wainwright reiterated coverage on [Keros Therapeutics (KROS)](in the Healthcare sector with a Buy rating and has set a price target of $100. Our data shows [Keros Therapeutics]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $87.40. In addition, TradingView issued a Sell rating for [KROS]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. [For the complete breakdown on KROS, please click here >>]( --------------------------------------------------------------- Sponsor [The New Epicenter for Lithium!]( company makes big acquisition in new epicenter of Lithium supply for EV's! [Get Symbol]( --------------------------------------------------------------- [Adobe, ADBE]( Summary: Adobe Inc. is one of the largest software companies in the world. Adobe picks up licensing fees from customers, which form the bulk of its revenue. The company also offers technical support and education, which account for the balance. The company operates through three segments. The Digital Media solutions segment enables small businesses and enterprises to create highly compelling content, deliver it across diverse media through smartphones, tablets, e-readers, and other devices, and then optimize it through systematic targeting and measurement. Within Digital Media, the two major components of revenue are the Creative family of products and Document Services products. The target customers are traditional content creators, web application developers, digital media professionals and user interface designers/developers, writers, videographers and photographers. Derrick Wood analyst at TD Cowen reiterated coverage on [Adobe (ADBE)](in the Technology sector with a Buy rating and has set a price target of $4. Our data shows [Adobe]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target of $519.80. In addition, TradingView issued a Buy rating for [ADBE]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the complete breakdown on ADBE, please click here >>]( [Cogent Biosciences, COGT]( Summary: Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass. Joel Beatty analyst at Robert W. Baird reiterated coverage on [Cogent Biosciences (COGT)](in the Healthcare sector with a Buy rating and has set a price target of $14. Our data shows [Cogent Biosciences]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $14.40. In addition, TradingView issued a Sell rating for [COGT]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on COGT, please click here >>]( --------------------------------------------------------------- Sponsor [New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia]( The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." [Early investors can reap 5,633% gains on the small company revolutionizing warfare ]( --------------------------------------------------------------- [Avantor, AVTR]( Summary: Avantor Inc. is a provider of critical products and services primarily to biopharma, healthcare, education & government, advanced technologies & applied materials industries. Avantor Inc. is based in Radnor, United States. Justin Bowers analyst at Deutsche Bank reiterated coverage on [Avantor (AVTR)](in the Basic Materials sector with a Hold rating and has set a price target of $22. Our data shows [Avantor]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $24.80. In addition, TradingView issued a Strong Buy rating for [AVTR]( over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the complete breakdown on AVTR, please click here >>]( [Bluebird Bio, BLUE]( Summary: bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.'The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent '-thalassemia (TDT). Jack Allen analyst at Robert W. Baird reiterated coverage on [Bluebird Bio (BLUE)](in the Healthcare sector with a Buy rating and has set a price target of $7. Our data shows [Bluebird Bio]( currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target of $6.06. In addition, TradingView issued a Strong Sell rating for [BLUE]( over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. [For the complete breakdown on BLUE, please click here >>]( --------------------------------------------------------------- Sponsor [ChatGPT, iOS and the Better AI Play...]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [FinancialMarketMovers.com]( --------------------------------------------------------------- Sponsor [New EV Lithium Player?]( company surges over 178% after recent acquisition in new Lithium epicenter! [See Report]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( FinancialMarketMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( This is part of your free subscription to FinancialMarketMovers. FinancialMarketMovers.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123